Governance

Transforming healthcare with integrity and transparency

Alert Icon

Upholding ethical standards for patients and society

At Ipsen, we pride ourselves on our commitment to integrity, transparency and upholding the highest ethical standards. A fundamental pillar of our Generation Ipsen – For Positive Change initiative, we are fostering responsible management while cultivating a strong ethical culture that permeates every level of our organization. Our dedication to governance excellence ensures we always act with the best interests of our patients, partners and society at heart.

Our approach to Governance is based on three core principles: 

  • Doing what is right. Not what is easy.  
  • Guided by our Strategy or Focus, Together for Patients & Society.  
  • Success delivered through responsible management.  
Author Image

Our governance approach emphasizes integrity and responsibility, prioritizing what’s right over what’s easy. Through our dedication to collaboration and ethical management, we consistently fulfill our promise to enhance lives with innovative healthcare solutions.

François Garnier

EVP, General Counsel and Chief Business Ethics Officer

Strengthening Business Ethics at Ipsen

Discover our commitment to responsible business practices, as we work to cultivate an ethical culture anchored in anti-corruption measures and transparency.

ISO 37001 anti-corruption certification

ISO 37001 anti-corruption certification

We are committed to fighting corruption and continuously enhancing our anti-corruption infrastructure. Demonstrating our dedication in this regard, we renewed our ISO 37001 certification in July 2022.

Global whistleblowing policy

Global whistleblowing policy

Implemented since 2018, our Global Whistleblowing Policy encourages employees to report potential non-compliant or unethical behaviors, fostering a speak-up culture and promoting transparency and accountability.

Employee ethical culture measurement

Employee ethical culture measurement

Our workforce exudes a strong ethical foundation. One way in which we measure the strength of our ethical culture is through annual employee surveys. In 2021, 90% of respondents reported considering compliance or ethical factors in their decision-making.

Reporting concerns

Reporting concerns

At Ipsen, we work to fairly address concerns that come to us. If you have an ethics issue, concern or grievance that you would like to report, you can raise your alert through the Whispli designated Alert Platform or use the email address Ipsen.Ethics.Hotline@ipsen.com

Media Image

Ipsen’s Code of Conduct

Ipsen’s Code of Conduct is a dynamic blueprint that emphasizes ethical decision-making, transparency and accountability across our diverse operations. This robust framework fuels an unwavering commitment to revolutionizing patient care, cultivating an empowering corporate culture, and exceeding industry standards and regulations.

Media Image

Combating corruption with ethics and transparency

At Ipsen, we proudly uphold ethical standards, integrity and transparency in all of our endeavors. Robust anti-corruption policies ensure strict adherence to all applicable national and international legislation, accurate financial recordkeeping, and stakeholder interactions based on integrity and merit.

Advancing ethical standards with governance actions

Ipsen continuously enhances its Business Ethics Program, backed by a robust infrastructure and governance system. By fostering a culture of ownership, accountability and mindful decision-making, we maintain a strong ethical foundation, as evidenced by positive employee survey results.

Ipsen is committed to ensuring a robust Opportunities and Risks Governance policy, with several strategic and operational committees actively working to identify, assess and address risks and opportunities.

In 2022, we implemented a comprehensive Supplier Risk Management process using a unified digital platform and engaging cross-functional experts to ensure potential suppliers meet our standards and Code of Conduct. This approach streamlines assessments and strengthens risk management throughout our organization.

 

Ipsen is dedicated to improving patients’ lives and firmly committed to our company ethical culture and social responsibility by supporting its employees and giving back to patients and society, as well as minimizing its impact on the environment

 

Ipsen recognizes that its business partners play an important role in Ipsen’s success and commitments.  Accordingly, our company strives to conduct business with individuals and organizations who share Ipsen’s commitment to ethical culture and operate in a socially and environmentally responsible manner

 

The Ipsen Business Partner Code of Conduct documents principles and expectations for establishing and maintaining a business relationship with all partners.

At Ipsen, we care about protecting the personal data of all our stakeholders. We ensure that we only use personal data as necessary, that our use of that data is lawful and fair, that we keep data secure, and that we inform individuals about how we use their data. We manage privacy compliance at Ipsen through policies, procedures and training, and by fostering a strong culture of respect for privacy.

We are committed to fostering transparency and trust in all of our collaborations with healthcare professionals (HCPs) and healthcare organizations (HCOs). By openly disclosing information on transfers of value, clinical trials, scientific publications and interest representation activities, we ensure integrity and promote a strong ethical foundation across our interactions.

 

Transparency rules and reports

 

Please follow the links to the countries to find the information about local Transparency rules and reports:

 

Austria

 

Belgium

 

Bulgaria

  • No transfer of value in 2018, 2019, 2021, 2022
  • 2020 EFPIA report in euro: Bulgarian
  • Methodological note : English

 

Croatia

  • 2016 EFPIA report in euro: English
  • 2016 EFPIA report in kuna: English
  • 2017 EFPIA report in euro : English
  • 2017 EFPIA report in kuna : English
  • No transfer of value in 2018, 2019, 2020, 2021, 2022
  • Methodological note: English

 

Cyprus 

  • No Transfer of value in 2018, 2020, 2021, 2022
  • 2019 EFPIA report in euro: English

 

Czech Replublic

 

Denmark

 

Estonia

 

Finland

 

France

 

Germany

 

Greece

  • 2018 EFPIA report in euro : Greek
  • 2019 EFPIA report in euro : Greek
  • 2020 EFPIA report in euro : Greek
  • 2021 EFPIA report in euro : Greek
  • 2022 EFPIA report in euro : Greek
  • Methodological note: Greek

 

Hungary

  • 2018 EFPIA report in forint : English
  • 2019 EFPIA report in forint : English
  • 2020 EFPIA report in forint : English
  • 2021 EFPIA report in forint : English
  • 2022 EFPIA repot in forint: English
  • Methodological note: English

 

Iceland

  • No Transfer of value in 2018, 2019, 2020, 2021, 2022

 

Ireland

 

Italy

 

Latvia

 

Lithuania

 

Luxemburg

  • 2018 EFPIA report in euro : English
  • 2019 EFPIA report in euro : English
  • No Transfer of value in 2020
  • 2021 EFPIA report in euro : English
  • 2022 EFPIA report in euro : English
  • Methodological note: English

 

Malta

  • No Transfer of value in 2018, 2019, 2020, 2021, 2022
  • Methodological note: English

 

Norway

 

Poland

 

Portugal

 

Romania

 

 

Russia

 

Serbia

  • No Transfer of value in 2018, 2019
  • 2020 EFPIA report in euro : English/ Serbian
  • 2021 EFPIA report in euro : English
  • 2022 EFPIA report in euro : English
  • Methodological note: English

 

Slovakia

 

Slovenia

  • No transfer of value in 2018, 2019, 2020
  • 2021 EFPIA report : English
  • 2022 EFPIA report : English
  • Methodological note: English

 

Spain

 

Sweden

 

Switzerland

 

The Netherlands

 

Ukraine

United Kingdom 

 

Ipsen actively collaborates with patient organizations to better understand and support patients’ needs. Emphasizing transparency, we publicly disclose financial and non-financial support provided to these organizations in adherence to the EFPIA Code.

 

Based on our dedication to transparency and under the EFPIA Patient Organizations Code, we make a list of patient organizations to which we provide financial support (grants, sponsorships, donations, etc. etc..) or significant non-financial support publicly available for viewing.

 

Motivated by our strategic commitment to society as a whole, we seek out opportunities to make an impact. In 2022, in response to the war in Ukraine, Ipsen donated €1.5 million to two organizations helping those impacted: disaster-relief organization Tulipe and the International Red Cross in France.

Ipsen is committed to transparency in clinical studies, providing readily accessible information on clinical trials to patients, healthcare professionals and researchers. We publicly disclose protocol summaries and trial results, adhering to global industry standards, and share anonymized clinical study data with qualified researchers through the data-sharing platform, Vivli.

 

  • Protocol Summary Disclosure

 

Protocol summaries of Ipsen sponsored clinical trials are made publicly available on the US Clinical Trials Registry (ClinicalTrials.gov) and on the EU Clinical Trials Register (www.clinicaltrialsregister.eu) at initiation of the clinical trial.

For Post-Authorization Safety Studies (PASS) and Post-Authorization Efficacy Studies (PAES) that are outside the scope of Directive 2001/20/EC, protocol summaries are posted in the EU electronic Register of Post-Authorization Studies (EU PAS Register) at initiation of the clinical trial.

We also provide clinical trial information to other national clinical trial registries or databases according to local requirements/legislation.

 

  • Disclosure of Clinical Trial Results

 

ClinicalTrials.gov

 

The results of Ipsen clinical trials are publicly posted to the results database after completion or termination of a clinical trial. Clinical trial results are usually available within 12 months of the trial completion or termination date. Results of clinical trials that are subject to FDAAA 801 legislation have been posted on ClinicalTrials.gov since June 2009. Since January 2014, Ipsen posts results from all Ipsen sponsored interventional clinical trials in patients.

 

EU Clinical Trials Register

 

From 21st July 2015, results summaries of Ipsen sponsored interventional clinical trials in patients conducted in the EU/EEA that completed from 21st July 2013 are available on the EU Clinical Trials Register. Results of interventional clinical trials are published one year after completion. From 21st July 2016, it is expected that all trials that started since May 2004 and completed before 21st July 2013 will also be made available here.

 

  • Sharing Clinical Trial Data with Qualified Researchers

 

Ipsen is committed to sharing anonymized clinical study data from completed Phase II to IV studies for products and indications approved in the United States and/or in the European Union, with a first patient included as of 1 Jan 2005 onwards. Ipsen is pleased to be member of the data sharing platform www.vivli.org. Available studies are listed on this platform. Ipsen will regularly update this list to add eligible studies. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board. Anonymized data will be provided to qualified researchers through Vivli’s platform upon approval of the research proposal and signature of a Data Use/Sharing Agreement.

 

Additional details on Ipsen data sharing policy are available here.

Ipsen does not have internal animal research facilities. Although Ipsen outsources its animal testing, it has put in place an Animal Welfare governance body ensuring the appropriate treatment of animals. We are signatories of Gircor’s “French Charter for Transparency on the Use of Animals for Scientific and Regulatory Purposes,” and actively pursue the 3Rs: reduction, refinement and replacement of animal experimentation.

 

Patients and society are at the core of Ipsen’s mission to improve lives and health outcomes. Biological and medical research are critical to continuously increasing scientific knowledge and improving human health. While animal studies continue to play an important role in the medical research process and in the development of treatments improving the quality of life of millions of people, it is our priority to meet the highest possible standards of animal welfare. That’s why we are among the signatories of the “French Charter for Transparency on the Use of Animals for Scientific and Regulatory Purposes” developed by the GIRCOR.

 

Ipsen’s Cell-Based Assay is now fully implemented for its DYSPORT® products supplied to the U.S., Canada, E.U. and Switzerland.

Our Early Access policy enables patients to obtain eligible Ipsen products that have not yet been approved by local health authorities, and thus otherwise unavailable for prescription.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.